Morgan Stanley analyst Sean Laaman raised the firm’s price target on Argenx (ARGX) to $1,110 from $1,070 and keeps an Overweight rating on the shares after the firm conducted a survey of 100 U.S. neurologists, focused on the treatment of chronic inflammatory demyelinating polyneuropathy and myasthenia gravis.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx downgraded to Peer Perform from Outperform at Wolfe Research
- argenx SE Shareholders Approve Remuneration Policy at Extraordinary Meeting
- Argenx price target raised to $1,124 from $1,041 at Citi
- Argenx removed from Best Ideas List at Wedbush
- Argenx: Strong Market Position and Growth Potential Justify Buy Rating